HOME >> MEDICINE >> NEWS
Tamoxifen for prevention of breast cancer encouraging results but risks still unclear

Early findings from a randomised trial investigating the effectiveness of tamoxifen to prevent breast cancer are reported in this week's issue of THE LANCET. Although tamoxifen reduced breast cancer incidence by a third compared with women given placebo, the authors of the study caution that it is still too early to fully assess the risk to benefit ratio of tamoxifen as a preventative strategy for breast cancer.

Tamoxifen is well known in its effect to decrease recurrence of (and death from) breast cancer; however, three clinical trials on the use of tamoxifen to prevent breast cancer have reported mixed results. The overall evidence supports a reduction in the risk of breast cancer, but whether this benefit outweighs the risks and side-effects associated with tamoxifen is unclear.

Jack Cuzick from Cancer Research UK, lead investigator of the International Breast Cancer Intervention Study (IBIS-I) and colleagues undertook a double-blind placebo-controlled randomised trial of tamoxifen, 20 mg/day for 5 years, in around 7000 women from the UK, Europe, Australia and New Zealand who were aged 3570 years and who were at an increased risk of breast cancer (eg. They had a Family history of the disease or had a benign lesion associated with an increased risk of breast cancer).

The frequency of breast cancer was reduced by a third among Women given tamoxifen (69 breast cancers in 3578 women in the tamoxifen group and 101 breast cancers in 3566 in the placebo group). Endometrial cancer--considered to be increased by tamoxifen use--was doubled in the tamoxifen group (11 instances compared with 5 in the control group), but this increase was not statistically significant, and all cases were localised (stage 1) and curable by hysterectomy.

However, tamoxifen use was associated with more than a doubling in the risk of blood-clotting complications, especially after surgery or long periods of immobilisation. The investigators comment that the incre
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-207-424-4949
Lancet
12-Sep-2002


Page: 1 2

Related medicine news :

1. Tamoxifens risks similar in African American and white women
2. Tamoxifen and estrogen have similar effects on the brain
3. Tamoxifen found to increase risk of endometrial cancer
4. Views Of Tamoxifen And Synthetic Estrogen In Action Provide Clues For Designing Better Drugs
5. International breast cancer prevention study launches in the United States and Canada
6. Cavity prevention tips for pre-school age children
7. HIV and ID doctors oppose ideologically driven STI prevention policies
8. School-based smoking prevention programs ineffective
9. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
10. Mount Sinai stroke prevention trial published in JAMA
11. New stroke-prevention drug unlikely to be cost-effective except in patients at high risk of bleeding

Post Your Comments:
(Date:4/19/2015)... April 19, 2015 The American Institute ... with PROSHRED Security (“PROSHRED”) to host its second annual, ... shred their personal documents in order to raise funds ... , The June 6th event is being held at ... 2pm local time. The time will vary at select ...
(Date:4/19/2015)... (PRWEB) April 19, 2015 HealthPostures, LLC ... announces that it will exhibit it’s pioneering ergonomics products ... and the Iowa-Illinois Safety Council Professional Development Conference and ... the TaskMate EZ are used in volume by call ... , Built to clamp to a desk, the ...
(Date:4/18/2015)... Carinsurancesavings.biz has released a new blog post explaining ... Spring. , Spring can be a great season ... sure they compare the newest policies before deciding on ... about Spring car insurance offers by reading the newly ... becoming more and more popular. Many insurance brokerage websites ...
(Date:4/18/2015)... 18, 2015 Insuranceautoquote.info has released a ... auto insurance quotes . , Clients can review ... website. The online environment provides important advantages for clients ... , Drivers who do not have coverage for their ... any season, day or hour. Many agencies offer important ...
(Date:4/18/2015)... the past few weeks, TheBeautyPlace.com has been undergoing maintenance ... run maintenance on our shipping facilities to update software ... Director. "It disrupted our regular shipping schedule but we ... track after having completed the maintenance." , Now, TheBeautyPlace.com ... has not allowed some calls to come in through ...
Breaking Medicine News(10 mins):Health News:2015 Annual Nationwide "Shred Cancer" Shredding Event 2Health News:HealthPostures' TaskMate Products to be Exhibited at the Wisconsin and Iowa-Illinois Safety Conferences 2Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:TheBeautyPlace.com Temporary Number Available 2
(Date:4/16/2015)... SHENZHEN, China , April 16, 2015 /PRNewswire/ ... a leading developer, manufacturer, and marketer of medical ... with the Securities and Exchange Commission an Annual Report ... for the year ended December 31, 2014. An electronic ... is available on Mindray,s investor relations website at  ...
(Date:4/16/2015)... , April 16, 2015  Amgen (NASDAQ: ... first quarter financial results on Tuesday, April 21, 2015, ... announcement will be followed by a conference call with ... the call from Amgen will be Robert A. ... members of Amgen,s senior management team. Live ...
(Date:4/16/2015)... Colo. , April 16, 2015  Rosewind ... completed a reverse merger with a newly formed ... an initial focus on addressing urological disorders. The ... Aytu BioScience Inc., has commenced operations and incorporates ... Luoxis Diagnostics.  The Company,s strategy is to build ...
Breaking Medicine Technology:Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2Amgen Announces Webcast Of 2015 First Quarter Financial Results 2Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 2Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 3
Cached News: